Lactobaccillus Rhamnosus PB01 Linked With Pain Management

13 Dec 2016 --- New research from Bifodan A/S has revealed that its proprietary strain, Lactobacillus Rhamnosus PB01, could have a positive effect on pain management. 

This study, titled “A Potential Nociceptive Regulatory Effect of Lactobacillus Rhamnosus PB01 (DSM 14870) On Mechanical Sensitivity In Diet-Induced Obesity Model” was recently published in ‘Pain Research and Management’.

The research was performed in collaboration with Aalborg University in Denmark and concludes that, when placed on a Lactobacillus rhamnosus PB01 supplemented diet, diet-induced, obese mice demonstrate a lower sensitivity to mechanical stimulation; a strong indication that this specific strain, may have potential to reduce the experience of pain.

“Regardless of the underlying mechanism, Lactobacillus Rhamnosus PB01 can be suggested as a candidate for a novel therapeutic strategy in pain management of obese and normal weight individuals,” says the author of the study, Dr. Feresteh Dardmeh from University of Aalborg .

Chief Scientific Officer at Bifodan, Erik Brandsborg continues: “Credible research is the strength behind our proprietary strains.”

“Our systematic screening of Lactobacillus Rhamnosus PB01 continues to reveal new strain-specific capabilities, which we are excited to explore further together with our scientific partners around the world.”

“Translating such findings into human application is one of our core competencies.”